Stanley Druckenmiller’s Teva Pharmaceuticals TEVA Stock Holding History

Stanley Druckenmiller’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.6M	Sell	2,377,285 -3,497,585	-60%	-$113M	2.12%	14
2025 Q4	$183M	Sell	5,874,870 -10,719,065	-65%	-$264M	4.08%	5
2025 Q3	$335M	Buy	16,593,935 +625,000	+4%	+$11M	8.25%	3
2025 Q2	$268M	Buy	15,968,935 +1,089,185	+7%	+$17.6M	6.57%	2
2025 Q1	$229M	Buy	14,879,750 +5,882,350	+65%	+$105M	7.47%	2
2024 Q4	$198M	Buy	8,997,400 +7,569,450	+530%	+$138M	5.33%	4
2024 Q3	$25.7M	Buy	+1,427,950	New	+$25M	0.87%	25
2015 Q2	–	Sell	-790,500	Closed	-$49.2M	–	43
2015 Q1	$49.2M	Buy	+790,500	New	+$46M	6.26%	6
2014 Q3	–	Sell	-1,241,000	Closed	-$65.1M	–	61
2014 Q2	$65.1M	Hold	1,241,000	–	–	4.64%	6
2014 Q1	$65.6M	Hold	1,241,000	–	–	7.4%	4
2013 Q4	$49.7M	Buy	+1,241,000	New	+$48.9M	3.31%	8

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley Druckenmiller's TEVA Position: Q1 2026 in Review

Stanley Druckenmiller reduced its Teva Pharmaceuticals (TEVA) stake by 60% in Q1 2026, selling an estimated $113M and leaving 2,377,285 shares worth $71.6M. The position accounts for 2.12% of the portfolio, ranked #14.

Stanley Druckenmiller first reported a position in TEVA in Q4 2013 and has held it in 11 quarters since. The position peaked at $335M in Q3 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Stanley Druckenmiller held 2,377,285 shares of Teva Pharmaceuticals worth $71.6M as of Q1 2026.
Stanley Druckenmiller sold 3,497,585 Teva Pharmaceuticals shares in Q1 2026, an estimated $113M.
Teva Pharmaceuticals made up 2.12% of Stanley Druckenmiller's portfolio in Q1 2026, its #14 holding.
Stanley Druckenmiller first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 11 quarters since.
Stanley Druckenmiller's Teva Pharmaceuticals position peaked at $335M in Q3 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.